Education
About Us
Working with TipRanks
Follow Us
Abcellera Biologics, Inc. (DE:8QQ)
:8QQ
8QQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.16 - €4.62
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00K
Market Cap
€742.22M
Enterprise Value€169.88M
Total Cash (Recent Filing)$7.55M
Total Debt (Recent Filing)$6.89M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 13, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding297,987,670
10 Day Avg. Volume780
30 Day Avg. Volume1,003
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.04
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
€6.72Price Target Upside141.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
AbCellera Biologics News
PremiumCompany Announcements
AbCellera Biologics’ Earnings Call: Transition Amid Challenges
PremiumCompany Announcements
AbCellera Biologics Reports 2024 Financial Results
PremiumCompany Announcements
AbCellera Biologics Reports 2024 Financial Results and Growth
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySolid balance sheet should provide ample runway to advance and expand the internal pipeline while executing on key strategic initiatives.
Strategic CollaborationsExpanded high-value collaboration with Abbvie shows continued co-development execution as clinical pipeline makes steady progress.
Bears Say
Financial PerformanceAbCellera reported 3Q-2024 financial results which were below estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
43.29% Insiders
0.36% Mutual Funds
24.75% Other Institutional Investors
30.45% Public Companies and Individual Investors
8QQ FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was €2.16 and its highest was €4.62 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is €742.22M.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 71 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on Feb 27, 2025. The company reported -€0.116 earnings per share for the quarter, beating the consensus estimate of -€0.128 by €0.013.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 297,987,670 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -€0.116 in its last earnings report, beating expectations of -€0.128. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in DE:8QQ
---
AbCellera Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.72 (141.65% Upside)
€6.72 (141.65% Upside)
Blogger Sentiment
Bullish
DE:8QQ Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.11%
12-Months-Change
Fundamentals
Return on Equity
-15.55%
Trailing 12-Months
Asset Growth
-7.89%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
8QQ Company Deck
---
8QQ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights AbCellera's successful transition to a clinical stage biotech with strong liquidity and strategic advancements in key programs and partnerships. However, the company faced challenges with declining revenue and a significant net loss, driven by high R&D expenses and reduced partnership activities.Read More>---
8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
8QQ Stock 12 Month Forecast
Average Price Target
€6.72
▲(141.65% Upside)
Technical Analysis
Best Analysts Covering 8QQ
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-31.75%
reiterated a buy rating 3 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -31.75% per trade.
---